Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
PT-141 is FDA-approved for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD)
Historically, centrally acting peptides were avoided due to concerns about neuropsychiatric side effects and bloodbrain barrier delivery
Redox signal-mediated sensitization of transient receptor potential melastatin 2 (TRPM2) to temperature affects macrophage functions
Thus, carnitine might hypothetically increase energy production in brain cells that are starting to slow down and trigger memory loss
US$ 24.91
US$ 25.85
US$ 28.04
